Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

622 results
Display

A general view of CD33⁺ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy

Fathi E, Farahzadi , Sheervalilou R, Sanaat Z, Vietor I

Acute myeloblastic leukemia (AML) is the most frequent acute leukemia in adulthood with very poor overall survival rates. In the past few decades, significant progresses had led to the findings...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study

Kim SH, Lee DE, Joung JY, Seo HK, Lee KH, Chung J

PURPOSE: This study aimed to compare progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) in Heng intermediate-risk patients with metastatic renal cell carcinoma (mRCC) treated with first-line immunotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?

Lee HW, Cho KJ, Park JY

Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of disease. Until recently, systemic treatment options that showed survival benefits in HCC have been limited to tyrosine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

Lim SM, Hong MH, Kim HR

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis

Oh SJ, Lee J, Kim Y, Song KH, Cho E, Kim M, Jung H, Kim TW

Cancer immunotherapy, in the form of vaccination, adoptive cellular transfer, or immune checkpoint inhibitors, has emerged as a promising practice within the field of oncology. However, despite the developing field's...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

Kim JH, Kim BS, Lee SK

Tregs have a role in immunological tolerance and immune homeostasis by suppressing immune reactions, and its therapeutic potential is critical in autoimmune diseases and cancers. There have been multiple studies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy

Jeong S, Park SH

Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Re-defining T-Cell Exhaustion: Subset, Function, and Regulation

Im SJ, Ha SJ

Acute viral infection or vaccination generates highly functional memory CD8 T cells following the Ag resolution. In contrast, persistent antigenic stimulation in chronic viral infection and cancer leads to a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B vaccination and immunotherapies: an update

Stasi C, Silvestri , Voller F

World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Status of Immunotherapy for Lung Cancer and Future Perspectives

Kim HC, Choi CM

Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma

Lee HW, Cho KJ, Shin SY, Kim HY, Lee EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH

BACKGROUND/AIMS: Programmed death receptor 1 (PD-1) is a promising new target for treatment of patients with hepatocellular carcinoma (HCC). A high expression level of programmed death-ligand 1 (PD-L1) is a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma

Yim SY, Lee JS

The pathogenesis of hepatocellular carcinoma (HCC) is a complex process. During the last decade, advances in genomic technologies enabled delineation of the genomic landscape of HCC, resulting in the identification...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Identification of neoantigens derived from alternative splicing and RNA modification

Park J, Chung YJ

The acquisition of somatic mutations is the most common event in cancer. Neoantigens expressed from genes with mutations acquired during carcinogenesis can be tumor-specific. Since the immune system recognizes tumor-specific...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Development and Research Trend of Chemotherapeutic Agents for Head and Neck Squamous Cell Carcinoma

Lee YS

After FDA approval of cetuximab at 2006, receptor tyrosine kinase, including an epidermal growth factor receptor, blocking agents have been evaluated for head and neck squamous cell carcinoma (HNSCC). Agents...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cellular immunotherapy in multiple myeloma

Vo MC, Lakshmi TJ, Jung SH, Cho D, Park HS, Chu TH, Lee HJ, Kim HJ, Kim SK, Lee JJ

In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bacillus Calmette-Guérin (BCG)-Cell Wall Skeleton as Immunotherapeutic Option for BCG-Refractory Superficial Bladder Cancer

Whang YM, Yoon DH, Hwang GY, Choi YW, Chang IH

Although intravesical instillation of Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the most successful cancer immunotherapy for superficial bladder cancer, the serious side effects are frequently arisen by using live mycobacteria....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Systematic Review of the Efficacy and Safety of Immune Checkpoint Inhibitor in Urological Cancers

Hwang GY, Choi SY, Chang IH

To systematically review relevant literature on efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with advanced and metastatic urothelial cell cancer (UCC), renal cell cancer (RCC), and prostate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk Factor Associated with Recurrence after OM-89 (Uro-Vaxom®) Treatment for Female Recurrent Cystitis

Han JY

PURPOSE: This study evaluated the risk factors associated with recurrence OM-89 (Uro-Vaxom®) treatment for female recurrent cystitis. MATERIALS AND METHODS: The medical records of patients who received OM-89 for at least...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Emerging Themes for the Role of Antibodies in Tuberculosis

Tran AC, Kim MY, Reljic R

The best way to debunk a scientific dogma is to throw irrefutable evidence at it. This is especially true if the dogma in question has been nurtured over many decades,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy

Arab S, Hadjati J

Immunotherapy has been introduced into cancer treatment methods, but different problems have restricted the efficacy of these protocols in clinical trials such as the presence of various immunomodulatory factors in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr